4.8 Review

Microglia modulate neurodegeneration in Alzheimer's and Parkinson's diseases

Journal

SCIENCE
Volume 370, Issue 6512, Pages 66-+

Publisher

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.abb8587

Keywords

-

Funding

  1. UK Dementia Research Institute (DRI) from DRI Ltd.
  2. UK Medical Research Council
  3. Alzheimer's Society
  4. Alzheimer's Research UK
  5. National Institute of Neurological Disorders and Stroke NIH [U54-NS110435, R01-NS109209, R21-NS107950]
  6. Michael J. Fox Foundation
  7. Parkinson's Disease Foundation Stanley Fahn Award [PF-JFA-1884]
  8. Eisai Pharmaceutical postdoctoral programme
  9. Chan Zuckerberg Collaborative Pairs Initiative
  10. MRC [UKDRI-1012, UKDRI-1011] Funding Source: UKRI

Ask authors/readers for more resources

Dementia is a rapidly rising global health crisis that silently disables families and ends lives and livelihoods around the world. To date, however, no early biomarkers or effective therapies exist. It is now clear that brain microglia are more than mere bystanders or amyloid phagocytes; they can act as governors of neuronal function and homeostasis in the adult brain. Here, we highlight the fundamental role of microglia as tissue-resident macrophages in neuronal health. Then, we suggest how chronic impairment in microglia-neuron cross-talk may secure the permanence of the failure of synaptic and neuronal function and health in Alzheimer's and Parkinson's diseases. Understanding how to assess and modulate microglia-neuron interactions critical for brain health will be key to developing effective therapies for dementia.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available